AstraZeneca

2025.04.09

15:04

Shares of London-listed pharmaceutical companies fell, with AstraZeneca falling 4.5% and GlaxoSmithKline falling 3.2%.

2025.04.03

21:30

U.S. stock market opens: three major indexes open sharply lower

The US tariff measures triggered panic in the market. The three major US stock indexes opened sharply lower, with the Dow Jones Industrial Average down 3%, the S&P 500 down 3.41%, and the Nasdaq down 4.6%. Large technology stocks led the decline, with Apple falling 8%, Broadcom, Amazon, Tesla, and Nvidia down more than 6%, and Microsoft down nearly 2%. AstraZeneca rose more than 4%, claiming that oral lipid-lowering drugs can reduce "bad cholesterol" by more than 50%.

2025.03.23

23:00

AstraZeneca Global CEO: Delivering "Made-in-China" drugs to more than 70 countries and regions around the world

AstraZeneca's global CEO Soriot said that China's supply chain is an important and stable pillar of AstraZeneca's global business. Relying on its high quality, high cost-effectiveness and efficient production capacity, we deliver Chinese-made medicines to more than 70 countries and regions around the world. On the same day, the China Development Forum 2025 Annual Meeting was held in Beijing. Soriot said during the forum that the importance of China's continued opening up is self-evident. The core lies in cooperation. Cooperation is the key to the successful development of new drugs. China's open environment will give rise to more cooperation opportunities.

08:16

Beijing Mayor Yin Yong meets with AstraZeneca's global CEO

On the afternoon of March 21, Beijing Mayor Yin Yong met with AstraZeneca's global CEO Soriot. Yin Yong said that with the further comprehensive deepening of reform and expansion of opening up, more pilot and open policies in the pharmaceutical field will be implemented in Beijing faster. We hope that AstraZeneca will make good use of Beijing's advantages, expand its R&D and investment layout in Beijing, promote more R&D pipelines to conduct clinical trials in Beijing, and help Beijing's pharmaceutical and health industry develop with high quality. Soriot said that China is gradually becoming an important source of global scientific and technological innovation. We are willing to further cultivate the Chinese market, take root in Beijing's development, make good use of Beijing's scientific and technological innovation resources, accelerate the implementation of drug R&D and clinical application cooperation in Beijing, achieve better cooperation and win-win results for both sides, and benefit more patients.

2025.03.21

19:09

AstraZeneca announces $2.5 billion investment to establish global strategic R&D center in Beijing

AstraZeneca announced on March 21 that it would invest $2.5 billion to establish its sixth global strategic research and development center in Beijing. The investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic and Technological Development Zone Management Committee, and includes agreements signed with three biotechnology companies (Harbour Biopharma, Syneron Bio and Kangtai Biological).

2025.03.17

15:39

AstraZeneca to buy Belgian biotech EsoBiotec for up to $1 billion

On March 17, AstraZeneca announced that it had agreed to acquire Belgian biotechnology company EsoBiotec for a total price of up to US$1 billion.

2025.03.03

14:00

Goldman Sachs has included AstraZeneca, Novo Nordisk and Rio Tinto on its European "confidence list".

2025.02.20

14:09

National Medical Products Administration: Support and guide domestic enterprises, research and development institutions, etc. to increase the research and development of innovative drugs and high-quality generic drugs

Recently, Huang Guo, member of the Party Leadership Group and deputy director of the State Drug Administration, led a team to Shandong to visit Qingdao Marine Biomedicine Research Institute, AstraZeneca Qingdao Inhalation Aerosol Production and Supply Base, and Qilu Pharmaceutical Co., Ltd. to conduct in-depth research on promoting high-quality development of the pharmaceutical industry. Huang Guo emphasized that the State Drug Administration attaches great importance to the research and development of innovative drugs and foreign cooperation. The drug regulatory department will further optimize the review and approval process, support the introduction of original research drugs into domestic production, and enhance the confidence of multinational companies in investing and developing in China; at the same time, it will continue to improve relevant policies, support and guide domestic enterprises, research and development institutions, etc. to increase the research and development of innovative drugs and high-quality generic drugs, and actively participate in the competition in both domestic and international markets.

2025.02.06

22:31

At the opening of the U.S. stock market, the Dow Jones Industrial Average rose 88 points, the S&P 500 rose 0.23%, and the Nasdaq rose 0.16%. Roblox (RBLX.N) fell 20%, and the company's daily active users in the fourth quarter were lower than expected. Ford Motor (FN) fell 4%, and the company predicted that the loss of its electric vehicle business would increase in 2025. AstraZeneca (AZN.O) rose 4.8%, and the company's revenue in 2024 increased by 21%. The Nasdaq China Golden Dragon Index rose 1.8%.

2025.02.01

00:22

UK government: Changes to AstraZeneca's (AZN.O) initial proposed investment structure resulted in a reduction in the amount of government funding.

2025.01.03

14:24

The first in China, Tagrisso was approved for the treatment of EGFR mutation stage III unresectable non-small cell lung cancer

On January 2, AstraZeneca announced that the National Medical Products Administration has approved its drug Tagrisso (generic name: osimertinib mesylate tablets) for the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) who have not experienced disease progression during or after platinum-containing chemoradiotherapy and have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations. It has also become the first and only targeted treatment option approved in China for stage III unresectable non-small cell lung cancer with EGFR mutations.

2024.12.20

09:10

Beijing Mayor Yin Yong meets with AstraZeneca's global CEO via video link

According to Beijing Yizhuang WeChat official account, on the afternoon of December 19, Beijing Mayor Yin Yong met with AstraZeneca's global CEO Soriot via video. Yin Yong said that the Chinese market has huge scale and development space, and it is still very attractive to companies from all countries. Beijing has rich medical science and education and clinical resources, strong demand in the medical and health market, and a booming pharmaceutical industry. In recent years, we have taken the pharmaceutical and health industry as an important direction for the development of high-end industries, accelerated the construction of high-level research hospitals, vigorously developed innovative drugs and medical devices, carried out pilot reforms in the field of medicine and health, and committed to building an ecological system for the entire industry chain, forming a spatial pattern of coordinated pharmaceutical and health industry development in the north and south. It is hoped that AstraZeneca will make full use of Beijing's advantages in basic medical research and industrial development, expand its R&D and industrial layout in Beijing, strengthen R&D cooperation with local universities, scientific research institutions, enterprises and other innovative entities, promote the implementation and transformation of more scientific and technological achievements in Beijing, and achieve a higher level of mutual benefit and win-win results.

2024.12.05

11:30

AstraZeneca China personnel adjustment, Lin Xiao appointed as AstraZeneca China General Manager

According to the 21st Century Business Herald, the reporter learned that Iskra Reic, the new global executive vice president and head of international business of AstraZeneca, issued an internal letter announcing that Lin Xiao will serve as the general manager of AstraZeneca China and Guan Dongmei will serve as the general manager of AstraZeneca China's oncology business. Lin Xiao and Guan Dongmei will become members of the global management team of the biopharmaceutical business unit and the oncology business unit respectively. Lin Xiao, Guan Dongmei, and Hu Yiqing, vice president of AstraZeneca China and head of the rare disease business unit, will all report directly to Iskra Reic, the global executive vice president and head of international business of AstraZeneca. In addition, according to AstraZeneca's disclosure to reporters, Lai Minglong serves as the head of AstraZeneca's global oncology business Dato-DXd and lung cancer business unit, and reports to Mr. Sunil Verma, AstraZeneca's global senior vice president and head of the oncology business unit.

2024.10.31

03:02

AstraZeneca's China president under investigation in China

Asia Tech Wire (Oct 31) -- AstraZeneca plc said Wednesday that Leon Wang, executive vice president for international and AstraZeneca China president, is cooperating with Chinese authorities in an investigation.

2024.10.25

08:06

BeiGene Greater China CCO said to be under investigation

Asia Tech Wire (Oct 25) -- Chinese biotech firm BeiGene's (BGNE:NASDAQ; 6160.HK) chief commercial officer for Greater China, Eva Yin, is said to be under investigation by Chinese regulators, according to recent market rumors.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Nvidia (NVDA.O): Blackwell chips have begun production at TSMC's chip factory in Phoenix, Arizona.
                            2025-04-14

                                    According to ABC News: The helicopter carrying the CEO of Siemens, his wife and young children crashed into the Hudson River in New York City.
                            2025-04-11

                                    BOE A: Net profit is expected to increase by 63% to 68% year-on-year in the first quarter of 2025
                            2025-04-15

                                    China Great Wall Information, a subsidiary of China Great Wall, won the bid for the AI acceleration server project of Heilongjiang Rural Credit Cooperatives
                            2025-04-11

                                    Nvidia concept sector continues to rise, Zhongdian Port and Hongbo shares hit the daily limit
                            2025-04-10